EUVIMEDEUVIMED entdecken
Kohortenstudie

Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study

T Khongyot, M N B Melgo, R Nurat, M Chanthachot, R Kochasen, W Homkaen, R Z Longakit, C Sunphakorn, N Detkaew, M Biswas, P Srikaew, S Dejrattanawichai und 1 weitere

Supportive Care in Cancer · 2026-07 · 34 (7)

DOI: 10.1007/s00520-026-10896-4 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 13.06.2026. Verfasst von T Khongyot und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Walailak University, Nakhon Si Thammarat, 80160, Thailand. Hauptthemen laut MEDLINE: Acrylamides, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Aniline Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Osimertinib is the preferred epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for patients with EGFR-mutant non-small cell lung cancer (NSCLC) due to its superior efficacy and favorable safety profile. Nevertheless, dermatologic toxicities remain common and may disrupt treatment continuity, underscoring the importance of effective supportive care. Evidence regarding the clinical impact of proactive skin toxicity management during osimertinib therapy in real-world settings remains limited. AIM: To evaluate the association between proactive versus reactive skin toxicity management and toxicity severity, treatment modification, and clinical outcomes in patients with EGFR-mutant NSCLC treated with osimertinib. METHODS: This retrospective cohort study included adult patients with advanced or recurrent EGFR-mutant NSCLC who received osimertinib at Surat Thani Hospital between January 2019 and January 2026. Patients were classified into a proactive skin toxicity management group, in which supportive skin care was initiated at the start of osimertinib therapy, or a reactive management group, in which skin toxicity management was initiated after the onset of dermatologic adverse events. Skin toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Multivariate logistic regression was used to evaluate the associations between skin toxicity management strategy (proactive vs reactive) and skin toxicity severity, osimertinib treatment modification, and objective response rate. Progression-free survival (PFS) was analyzed using Kaplan-Meier methods and Cox proportional hazards models. RESULTS: A total of 120 patients were included (60 per group), with comparable baseline characteristics. The overall incidence of skin toxicity did not differ between the proactive and reactive management groups (60.0% vs 53.3%, p = 0.290). However, proactive management was independently associated with a substantially lower risk of severe skin toxicity (adjusted odds ratio [OR] 0.122; 95% confidence interval [CI] 0.022-0.681; p = 0.006). Temporary and permanent treatment discontinuations due to skin toxicity were significantly reduced in the proactive group (both p < 0.001). Patients receiving proactive management demonstrated a higher objective response rate (78.3% vs 38.3%; adjusted OR 5.640; p < 0.001) and longer median PFS (14.0 vs 10.0 months; hazard ratio 0.313; 95% CI 0.163-0.600; p < 0.001). CONCLUSION: Proactive skin toxicity management during osimertinib therapy does not reduce the incidence of dermatologic adverse events but significantly mitigates toxicity severity, improves treatment continuity, and is associated with superior clinical outcomes compared with reactive management. These findings highlight the clinical value of proactive, supportive care-oriented skin management strategies to optimize osimertinib treatment in routine oncology practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesLung NeoplasmsCarcinoma, Non-Small-Cell LungAniline CompoundsProtein Kinase InhibitorsAntineoplastic AgentsDrug EruptionsHumansIndolesPyrimidinesRetrospective StudiesFemaleMaleAgedErbB ReceptorsMiddle AgedMutationAged, 80 and overCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

EGFR-mutant non-small cell lung cancerDermatologic toxicityOsimertinibProgression-free survivalProphylactic managementSupportive care

Substanzen

IndolesosimertinibPyrimidinesAcrylamidesAniline CompoundsErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Walailak University, Nakhon Si Thammarat, 80160, Thailand.
  • Department of Pharmacy, School of Health Care Professions, University of San Carlos, Nasipit, Talamban, 6000, The Philippines.
  • Department of Pharmacy, Thani Hospital, Surat Thani, 84000, Thailand.
  • Department of Pharmacy, University of Rajshahi, Rajshahi, 6205, Bangladesh.
  • Department of Medical Oncology, Surat Thani Hospital, Surat Thani, 84000, Thailand.
  • Department of Medicine, Maharaj Nakhon Si Thammarat Hospital, Nakhon Si Thammarat, 80000, Thailand.

Zitieren

APA

Khongyot, T., Melgo, M. N. B., Nurat, R., Chanthachot, M., Kochasen, R., Homkaen, W., Longakit, R. Z., Sunphakorn, C., Detkaew, N., Biswas, M., Srikaew, P., Dejrattanawichai, S., & Majam, T. (2026). Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study. Supportive Care in Cancer, 34(7). https://doi.org/10.1007/s00520-026-10896-4

Vancouver

Khongyot T, Melgo MNB, Nurat R, Chanthachot M, Kochasen R, Homkaen W, et al. Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study. Supportive Care in Cancer. 2026;34(7). doi:10.1007/s00520-026-10896-4

BibTeX
@article{Khongyot2026,
  author = {Khongyot, T and Melgo, M N B and Nurat, R and Chanthachot, M and Kochasen, R and Homkaen, W and Longakit, R Z and Sunphakorn, C and Detkaew, N and Biswas, M and Srikaew, P and Dejrattanawichai, S and Majam, T},
  title = {Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {7},
  doi = {10.1007/s00520-026-10896-4}
}
Kostenlos starten →